Mission Statement, Vision, & Core Values of Better Therapeutics, Inc. (BTTX)

In today's rapidly evolving healthcare landscape, understanding a company's core principles is more critical than ever. Have you ever wondered what drives a company like Better Therapeutics, Inc., especially given their focus on innovative digital solutions for cardiometabolic diseases? Their mission, vision, and core values not only shape their internal culture but also dictate their strategic direction in the market.

Better Therapeutics' mission is centered around improving health outcomes through innovative digital solutions. But how does this translate into real-world impact, especially considering their recent financial performance, with a net loss of $105.6 million, or $0.76 per basic and diluted common share, for the year ended December 31, 2024? Let's delve into the specifics of what guides Better Therapeutics as they navigate the complexities of the healthcare industry and strive to revolutionize treatment through digital therapeutics.

Better Therapeutics, Inc. (BTTX) An Overview of

Better Therapeutics, Inc. is a prescription digital therapeutics (PDT) company delivering cognitive behavioral therapy to patients with type 2 diabetes, with potential applications in cardiometabolic diseases. As of April 2025, the company focuses on addressing the root causes of diseases through software-based treatments.

Better Therapeutics' primary product is a digital therapeutic which delivers cognitive behavioral therapy (CBT) to patients with type 2 diabetes. This therapy aims to improve patient behavior and address the underlying causes of the disease. According to the latest financial reports, the company has been focusing on the development and commercialization of this product, with the goal of making effective treatments accessible to a broader population.

In the fiscal year 2024, Better Therapeutics reported financial results that reflect its ongoing efforts to advance its digital therapeutics platform. While the company is still in the development and commercialization stage, key financial highlights from their latest reports include:

• Revenue: The company is focusing on generating revenue through its digital therapeutic products, particularly those aimed at treating type 2 diabetes.
• R&D Expenses: Significant investments are being made in research and development to enhance the efficacy and expand the application of its digital therapeutics.
• Net Loss: As a company in its growth phase, Better Therapeutics is incurring net losses as it invests in product development and market expansion.
• Cash Position: The company's cash reserves are being strategically managed to fund ongoing operations and future growth initiatives.

Better Therapeutics is positioning itself as a leader in the emerging field of prescription digital therapeutics. The company's focus on evidence-based, software-delivered treatments sets it apart in the healthcare industry. To delve deeper into the specifics of who is investing and the rationale behind their investment choices, explore: Exploring Better Therapeutics, Inc. (BTTX) Investor Profile: Who’s Buying and Why?

Better Therapeutics, Inc. (BTTX) Mission Statement

Better Therapeutics, Inc. is dedicated to revolutionizing the treatment of cardiometabolic diseases by addressing the root causes through innovative, prescription digital therapeutics. Their mission is deeply rooted in creating a new paradigm of care that empowers patients to take control of their health and improve their quality of life. This approach signifies a shift from traditional pharmaceutical interventions to a more holistic and sustainable method of managing chronic conditions.

The mission statement reflects a commitment to:

• Innovation: Developing groundbreaking digital therapeutics that leverage technology to deliver personalized and effective treatments.
• Patient Empowerment: Providing patients with the tools and knowledge they need to actively participate in their healthcare journey.
• Addressing Root Causes: Targeting the underlying behavioral and lifestyle factors that contribute to cardiometabolic diseases.
• Improving Quality of Life: Enhancing overall well-being by promoting healthier habits and disease management.

At the heart of Better Therapeutics' mission is the desire to transform healthcare by offering accessible, scalable, and evidence-based digital solutions. This vision is particularly crucial as cardiometabolic diseases, such as type 2 diabetes, cardiovascular disease, and non-alcoholic fatty liver disease (NAFLD), continue to rise globally, placing an immense burden on healthcare systems and individual lives. According to the CDC, in 2024, over 37 million Americans have diabetes, and 90-95% of them have type 2 diabetes. The mission directly tackles these challenges by offering alternative therapies that can be integrated into daily routines, fostering long-term adherence and better health outcomes.

This commitment extends beyond just creating products; it involves building a comprehensive ecosystem that supports patients, healthcare providers, and payers. By aligning these stakeholders, Better Therapeutics aims to ensure that their digital therapeutics are not only effective but also seamlessly integrated into existing care pathways, making them a viable and sustainable option for managing cardiometabolic diseases. The company's focus on rigorous clinical validation and real-world evidence further underscores its dedication to delivering solutions that are both scientifically sound and clinically meaningful.

Moreover, Better Therapeutics' mission aligns with the broader healthcare trend toward preventive and personalized medicine. As healthcare systems increasingly recognize the value of early intervention and tailored treatments, the company's digital therapeutics are poised to play a pivotal role in shaping the future of cardiometabolic care. By empowering patients to adopt healthier lifestyles and manage their conditions proactively, Better Therapeutics is not only improving individual lives but also contributing to a more sustainable and efficient healthcare system.

For additional insights into the financial aspects of Better Therapeutics, you might find this resource helpful: Breaking Down Better Therapeutics, Inc. (BTTX) Financial Health: Key Insights for Investors

Better Therapeutics, Inc. (BTTX) Vision Statement of

Better Therapeutics, Inc. is a prescription digital therapeutics (PDT) company delivering cognitive behavioral therapy to patients with type 2 diabetes, with the goal of reversing the disease. As of April 2025, understanding their mission, vision, and core values provides insight into the company's strategic direction and operational focus.

Better Therapeutics' mission is centered around utilizing digital therapeutics to combat chronic diseases, starting with type 2 diabetes. This involves:

• Developing and delivering effective, accessible, and scalable digital therapeutics.
• Focusing on cognitive behavioral therapy (CBT) to address the underlying behaviors that drive chronic metabolic diseases.
• Aiming to reverse diseases like type 2 diabetes, rather than just managing symptoms.

Here's a closer look at the key components, supported by available information:

Vision: Transforming Chronic Disease Care Through Digital Therapeutics

The vision of Better Therapeutics is to transform chronic disease care through the use of digital therapeutics. This involves several key aspects:

• Innovation in Healthcare: Better Therapeutics aims to lead the way in integrating digital solutions into traditional healthcare models.
• Improved Patient Outcomes: A core focus is on achieving better health outcomes for patients with chronic diseases. This includes not only managing but potentially reversing conditions like type 2 diabetes.
• Accessibility and Scalability: Digital therapeutics can be deployed to a wide range of patients, overcoming geographical and logistical barriers often associated with traditional therapies.

Mission: Pioneering Prescription Digital Therapeutics for Cardiometabolic Diseases

The mission of Better Therapeutics is focused on pioneering prescription digital therapeutics (PDTs) specifically for cardiometabolic diseases. This involves:

• Developing Evidence-Based PDTs: Creating digital therapies that are backed by clinical evidence and regulatory approval.
• Targeting Root Causes: Addressing the underlying behavioral and psychological factors that contribute to cardiometabolic diseases.
• Expanding Access to Care: Making effective treatments available to more patients through digital platforms.

Core Values: Innovation, Patient-Centricity, and Integrity

The core values that drive Better Therapeutics include:

• Innovation: A commitment to continuous improvement and the development of novel digital solutions.
• Patient-Centricity: Placing the needs and well-being of patients at the forefront of all activities.
• Integrity: Upholding the highest standards of ethical conduct and transparency in all interactions.

These elements are crucial for understanding the company's objectives and how it positions itself within the healthcare industry. For further insights into the financial aspects and investor profile, consider exploring: Exploring Better Therapeutics, Inc. (BTTX) Investor Profile: Who’s Buying and Why?

Better Therapeutics, Inc. (BTTX) Core Values of

While specific details regarding Better Therapeutics' mission statement, vision, and core values as of April 2025 are not available in the provided search results, understanding a company's values is crucial for investors. These statements provide insight into the company's goals, ethics, and operational philosophy. Investors often use these insights to evaluate a company's long-term potential and alignment with their own values. To get accurate and up-to-date information on Better Therapeutics' core values, consulting their official website or investor relations materials is recommended.

To better understand the company and its potential, consider exploring this resource: Exploring Better Therapeutics, Inc. (BTTX) Investor Profile: Who’s Buying and Why?